During the past 3 years, the average Free Cash Flow per Share Growth Rate was 49.20% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 39.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of GT Biopharma was 49.20% per year. The lowest was 24.10% per year. And the median was 39.65% per year.
Competitive Comparison of GT Biopharma's 3-Year FCF Growth Rate
For the Biotechnology subindustry, GT Biopharma's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GT Biopharma's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GT Biopharma's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where GT Biopharma's 3-Year FCF Growth Rate falls into.
GT Biopharma 3-Year FCF Growth Rate Calculation
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
GT Biopharma 3-Year FCF Growth Rate Related Terms
Thank you for viewing the detailed overview of GT Biopharma's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GTBP has been successfully added to your